Provention Bio announces leadership team expansion

Pipette with drop of color liquid and petri dishes

Red Bank-based Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, has appointed Christina Yi as chief operations officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as chief quality officer, responsible for all aspects of quality.

“We are very excited for Christina and Ben to be joining our leadership team at this time, as we ready ourselves for what we believe will be an exciting and highly meaningful year in the growth and evolution of Provention Bio,” said Ashleigh Palmer, Provention Bio’s co-founder and CEO. “Both Christina and Ben have tremendous track records of leadership and success throughout their distinguished careers, and we look forward to their immediate contributions and impact as we progress in our efforts to commercialize teplizumab, focus on the subsequent potential teplizumab label expansion and life-cycle development, and continue to advance and reinforce our therapeutic pipeline targeting the interception and prevention of life-threatening autoimmune diseases.”

Yi joins Provention Bio as an accomplished biopharmaceutical leader with over 20 years of success across multifunctional operations, including manufacturing, distribution, technical operations, program management, human resources and information technology. Most recently, Yi served as chief operating officer at Vaxxinity, developing vaccines for neurological disorders and prevalent chronic disorders. Prior to joining Vaxxinity, she served as chief operations officer for Dendreon Pharmaceuticals and served in roles of increasing responsibility at Amgen Inc.

Osorio joined Provention Bio in 2020 and has served as the company’s senior vice president of quality since that time. Prior to joining the company, Osorio was chief operating officer at Progenics Pharmaceuticals. He previously held roles of increasing scopes of responsibility across a number of biopharmaceutical organizations, including Acorda Therapeutics, Achillion Pharmaceuticals, Valeant Pharmaceuticals, Breaburn Pharmaceuticals, Forest Laboratories and Purdue Pharma.